Evrópusambandið - íslenska - EMA (European Medicines Agency)

janssen-cilag international n.v. - telaprevir - lifrarbólga c, langvinn - veirueyðandi lyf til almennrar notkunar - incivo, ásamt sýnt alfa og sögu, er ætlað fyrir meðferð arfgerð-1 langvarandi lifrarbólgu c í fullorðinn sjúklinga með bætt lifrarsjúkdóm (þar á meðal skorpulifur):sem eru í meðferð barnaleg;sem hefur áður verið í meðferð með sjúklinga alfa (mjög eða ekki mjög) einn eða í bland með sögu, þar á meðal relapsers, að hluta svörun og núll svörun.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

molmed spa - Ósamgena t-frumurnar erfðabreytt með retróveira vektor kóðun fyrir styttu mynd af mönnum lágt skyldleiki taug vöxt þáttur viðtaka (Δlngfr) og herpes simplex ég veira thymidine nt (herpes-tk mut2) - hematopoietic stem cell transplantation; graft vs host disease - Æxlishemjandi lyf - zalmoxis er fram eins og venjulega meðferð í haploidentical skurðaðgerðir stafa klefi ígræðslu (hsct) af fullorðnum sjúklinga með hár-hættu blóðfræðileg illkynja.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - ipilimumab - melanoma; carcinoma, renal cell; carcinoma, non-small-cell lung; mesothelioma, malignant; colorectal neoplasms - Æxlishemjandi lyf - melanomayervoy as monotherapy or combination with nivolumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older (see section 4.  yervoy in combination with nivolumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults. relative to nivolumab monotherapy, an increase in progression-free survival (pfs) and overall survival (os) for the combination of nivolumab with ipilimumab is established only in patients with low tumour pd-l1 expression (see sections 4. 4 og 5. renal cell carcinoma (rcc)yervoy in combination with nivolumab is indicated for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma (see section 5. non-small cell lung cancer (nsclc)yervoy in combination with nivolumab and 2 cycles of platinum-based chemotherapy is indicated for the first-line treatment of metastatic non-small cell lung cancer in adults whose tumours have no sensitising egfr mutation or alk translocation. malignant pleural mesothelioma (mpm)yervoy in combination with nivolumab is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma. mismatch repair deficient (dmmr) or microsatellite instability-high (msi-h) colorectal cancer (crc)yervoy in combination with nivolumab is indicated for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine based combination chemotherapy (see section 5. oesophageal squamous cell carcinoma (oscc)yervoy in combination with nivolumab is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell pd-l1 expression ≥ 1%.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

astellas pharma europe b.v. - enzalutamíð - blöðruhálskirtli - innkirtla meðferð - xtandi is indicated for:the treatment of adult men with metastatic hormone-sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (see section 5. the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (crpc) (see section 5. the treatment of adult men with metastatic crpc who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. the treatment of adult men with metastatic crpc whose disease has progressed on or after docetaxel therapy.

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

le vet beheer b.v. - ciclosporinum inn - mixtúra, lausn - 50 mg/ml

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

krka sverige ab - enalaprilum maleat - tafla - 5 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

krka sverige ab - enalaprilum maleat - tafla - 20 mg

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

krka sverige ab - enalaprilum maleat - tafla - 10 mg

Evrópusambandið - íslenska - EMA (European Medicines Agency)

correvio - vernakalant stutt og long-term - gáttatif - hjarta meðferð - hraðri viðskipti á undanförnum upphaf gáttum tif að sínustakti í fullorðnir:fyrir utan sjúklingum skurðaðgerð: gáttum tif .

Evrópusambandið - íslenska - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - línaklótíð - ertanlegt þarmasvepp - lyf við hægðatregðu - constella er ætlað til meðferðar við meðhöndlun á meðallagi til alvarlega einkennum í þarmi með hægðatregðu (ibs-c) hjá fullorðnum.